Christopher Richard Anzalone - 18 Sep 2023 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
18 Sep 2023
Net transactions value
-$1,349,886
Form type
4
Filing time
20 Sep 2023, 18:10:16 UTC
Previous filing
05 May 2023
Next filing
27 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Options Exercise $274,336 +57,755 +1.5% $4.75* 3,819,093 18 Sep 2023 Direct F1
transaction ARWR Common Stock Sale $882,644 -31,523 -0.83% $28.00 3,787,570 18 Sep 2023 Direct F1, F2
transaction ARWR Common Stock Sale $741,579 -26,232 -0.69% $28.27 3,761,338 18 Sep 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARWR Stock Option (right to buy) Options Exercise $0 +57,555 +16% $0.000000 409,225 18 Sep 2023 Common Stock 57,555 $4.75 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.54 to $28.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $28.94, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 Represents first vesting date. Option vested over four years from the first vesting date.
F5 Represents total stock options beneficially owned at various strike prices